Biosimilars [Design Issues]

posted by Ben – 2011-12-16 20:04 (4069 d 08:55 ago) – Posting: # 7784
Views: 4,580

Dear Helmut/all,

you wrote

❝ Although GLs consider cross-over studies the ‘Gold Standard’ in all (!) studies I have personally seen (and know of from other people as well) a significant sequence effect was observed. Maybe a parallel design is the better option.

Is there a specific reason why this is so? I mean, this sounds like the problem of having a sequence effect always occurs when having biosimilars. What is so "special" about them causing sequence (or carryover or trt*prd interaction) effects?


Complete thread:

UA Flag
 Admin contact
22,479 posts in 4,709 threads, 1,603 registered users;
19 visitors (0 registered, 19 guests [including 9 identified bots]).
Forum time: 05:00 CET (Europe/Vienna)

The rise of biometry in this 20th century,
like that of geometry in the 3rd century before Christ,
seems to mark out one of the great ages or critical periods
in the advance of the human understanding.    R.A. Fisher

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz